Form 4: BioAge CFO Dov Goldstein Granted 110,000 Stock Options

BioAge Labs' Chief Financial Officer, Dov A. Goldstein, was granted 110,000 stock options with an exercise price of $19.63, vesting monthly over four years.

Summary

• Dov A. Goldstein, Chief Financial Officer of BioAge Labs, Inc. (BIOA), was granted 110,000 stock options.
• The options have an exercise price of $19.63 per share.
• The grant date for these options was February 17, 2026.
• The options vest monthly over a 48-month period (1/48th of the total award monthly).
• The first vesting tranche occurred on February 1, 2026, with subsequent tranches vesting on the monthly anniversary thereafter.
• The options are subject to Mr. Goldstein's continued service to the Issuer.
• The expiration date for these options is February 16, 2036.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive event, as it represents a standard executive compensation practice that aligns the CFO's interests with the company's long-term performance, without indicating any immediate operational or financial changes.

Positives

• The grant of 110,000 stock options to the Chief Financial Officer aligns management's interests with shareholder value creation.
• The vesting schedule incentivizes long-term commitment and performance from a key executive.

Risks

• The options are subject to the reporting person's continued service to the Issuer, meaning unvested options would be forfeited upon departure.
• The value of the options is dependent on the future stock price of BioAge Labs, Inc. exceeding the exercise price of $19.63.

Future Outlook

The filing does not contain specific forward-looking statements or guidance regarding the company's future performance, beyond the vesting schedule of the granted options which incentivizes long-term executive retention.

Industry Context

StockSavvy.ai notes that executive stock option grants are a common practice in the biotechnology and pharmaceutical industries, particularly for growth-oriented companies like BioAge Labs, Inc., to attract, retain, and motivate key talent. This grant is consistent with standard compensation practices aimed at aligning executive incentives with long-term shareholder value.

Stakeholder Impact

• Shareholders: Potential positive impact through increased alignment of executive incentives with long-term stock performance.
• Employees: No direct impact mentioned, but could signal stability in executive leadership.

Next Steps

• Continued monthly vesting of the stock options over the next 48 months, subject to the CFO's ongoing service.

Key Dates

Recommendation

This Form 4 filing reports a routine executive compensation event (stock option grant) for BioAge Labs' CFO. While it aligns management incentives, it does not provide new fundamental information about the company's operations, financial performance, or strategic direction that would warrant a change in investment recommendation. Investors should hold and await more substantive operational or financial updates.

Keywords

BioAge Labs, BIOA, Stock Option, Dov Goldstein, CFO, Executive Compensation, Form 4, Insider Transaction, Equity Grant, Vesting